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Abstract: Based on the concept that the tumorogenesis in chronic lymphocytic leukaemia comprises both an initial, inherited 
mutation and subsequent somatic mutations, the pleiotypic diversity of familial chronic lymphocytic leukaemia and related 
malignant lymphoproliferative disorders is generally explained by a repertoire of monoallelic polygenes in the initial muta-
tion. Epigenetic genomic imprinting is a likely mechanism behind of the asynchroneous replicating monoallelic polygenes 
which is discussed in the light of pleiotrophy and birth order effect. Furthermore, it is discussed that one possible mechanism 
available for the epigenetic transfer of these genes could be the physiological pregnancy-related microchimerism between 
mother and fetus.
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It is generally accepted that chronic lymphocytic leukemia (CLL) is a monoclonal B-lymphoproliferative 
disorder caused by a mutation in the differentiation pathway of the B-lymphocyte and that this mutation 
causes an arrest in the differentiation with accumulation of the leukemic subset of immature monoclonal 
B-lymphocytes. Since these B-lymphocytes are genuinely circulating in blood and lymph, the leukemic 
cells are spread to all part of the body with vessels and accumulated especially in bone marrow, lymph 
nodes and spleen and sometimes even in lamina propria and in other extra-lymphoid tissues [1–5]. 
Related monoclonal lymphocytic disorders (LDs) such as the other chronic leukemias (Waldenström´s 
macroglobulinemia, hairy cell leukemia, prolymphocytic leukemia and lymphoma cell leukemia), non-
Hodgkin lymphomas, Hodgkin´s disease and multiple myeloma are deﬁ  ned from their speciﬁ  c mutated 
arrests in the differentiation and ampliﬁ  cation [2,6].
The multistep evolution of LD is based on a paradigm (Figs. 1 and 2) comprising two different types 
of mutations (i) an initial mutation most likely under the inﬂ  uence of genetic factors, and (ii) subsequent 
somatic mutations which to our knowledge today are not convincingly genetically disposed. The purpose 
of the present paper is to discuss the inﬂ  uence of imprinting and microchimerism in the genetics of CLL 
and related LDs.
Evidence of Heredity
A hereditary mechanism in CLL and LDs is seen from the marked familial clustering with pleiotrophy, 
which means familial co-expression of CLL and LDs [7–17]. The hereditary momentum of these 
disorders is furthermore reﬂ  ected by the fact that one major risk factor of CLL is the presence of another 
family member with CLL and/or another type of LD and that CLL ethnically is mainly seen among 
people from the Western world [18].
However, to date the gene or genes involved have not been identiﬁ  ed. A considerable number of 
publications on gene-defects in CLL address the subsequent somatic mutations (Fig. 1). There is no 
proof for the otherwise common assumption that the diagnostic FISH aberrations and VH proﬁ  les of 
the subsets of CLL are the primary and inheritable chromosomal defects. On the contrary, they are rather 16
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“phenotypes” for survival pathways of the subsets 
through the tumorogenesis (Fig. 2), sometimes 
unspeciﬁ  c to such an extent that they hardly can 
act as candidates to a primarily genetic defects. As 
for example the Philadelphia defect t(9; 22) which 
is demonstrable both in chronic myelogenous 
leukemia, acute lymphoblastic leukemia and in 
some types on non-Hodgkin´s lymphomas [19].
Neither linking studies [20–27] nor genome-
wide screening [for review see 28] have exposed 
this or these genes related to the initial mutations. 
Their mode of transfer from generation to genera-
tion in affected families remains uncertain. A 
number of large-scaled computerized estimations 
of data from cancer registries conﬁ  rm the pleio-
trophic clustering and point out CLL as the subset 
of clustered LDs with the highest frequency. Thus, 
CLL is the most common diagnosis within LD 
having a stronger relative risk (RR) between two 
family members with CLL than between two fam-
ily members with other combinations of LDs in 
some of the studies published, but so far, there are 
no hints to a possible Mendelian pattern of the 
genetic segregation. A remarkable ﬂ  uctuation in 
the calculated RR within the entity of LD from 
different registries is reported from these studies 
[7–12]. The problems with such large-scaled reg-
istrations are changed deﬁ  nitions of disease with 
a new taxonomic system for LDs nearly every 10th 
year (Gall and Mallory, 1942; Rappaport, 1956; 
Good and Finstad, 1967, the Kieler Classiﬁ  cation 
1972, Working Formulation 1982 Real Classiﬁ  ca-
tion 1994) up to the present WHO Formulation 
from 2001 [ 2 ] including redeﬁ  nition of established 
disorders based on molecular-biological criteria, 
and the presence of low-grade conditions without 
clinical symptoms as for example MGUS (mono-
clonal gammopathy of uncertain signiﬁ  cance) and 
CLUS (chronic lymphocytosis of uncertain sig-
niﬁ  cance) with unknown incidences which, after 
all, make it highly difﬁ  cult to compare LDs-data 
on incidences and frequencies from the past cen-
turies covering the past generations in epidemio-
logical studies. The power of these association 
studies can be enhanced using selected cases with 
a family history of LDs. Such genealogical studies 
(segregation analysis) of pedigrees do neither point 
out a speciﬁ  c pattern of genetic mechanism apart 
from the general ﬁ  nding that a genetic mode is 
undoubtedly on question [29].
Whether the somatic mutations in the develop-
ment of LDs (Figs. 1 and 2) also are inﬂ  uenced by 
Figure 1. Pathogenesis of the lymphoproliferative disorders. The model is based on the assumption that an initial, inherited stem cell muta-
tion with subsequent somatic mutations cause pleiotypic segregation of the different diagnoses within the entity of LPD, for example the 
acute and chronic lymphocytic leukemias, malignant lymphomas including Hodgkin´s disease and multiple myeloma.17
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genetic factors is a matter for further discussion. 
Antigenic drive from for example Helicobacter 
pylori [30], HIV, EBV and hepatitis C virus [31,32] 
are well known stimulators for the development of 
LDs and thus, the genetic disposition to acquire 
and express such infections and the possible birth 
order effect caused by chronic contamination from 
older sibs have been brought into attention [33–36]. 
A birth order effect denotes an unequal and non-
random occurrence of affected offspring in the 
sibship where the rank of affected and unaffected 
sibs is not as would be expected from a simple 
Mendelian segregation. A birth order effect can be 
due to non-genetic mechanism such as environ-
mental infections or to parents´ decision after 
having had an affected offspring but certainly, a 
birth order effect can also be due to a genetic effect 
as a consequence of a pseudo-Hardy Weinberg 
formulation [37–39].
Imprinting and Pregnancy Related 
Microchimerism
One of the major recent contributions to the discus-
sion on familial CLL is the demonstration of a 
likely monoallelic polygene model where each 
monoallelic gene confer a small relative risk which 
increases when the monoalleleic genes occur in 
multiplicative and/or additional combinations 
[28,40–43].
If the interacting monoallelic polygenes arises 
as a consequence of inherited and initial mutations 
they mimic an autosomal dominant syndrome in 
which the individual cells in the mutated clone 
Figure 2. Pathogenesis of chronic lymphocytic leukemia (CLL). By deﬁ  nition, CLL is a mutated monoclone of B-lymphocytes with the expres-
sion of CD5, CD19, CD20, CD23 and weak SmIg. This monoclone has a growth-pattern different from normal lymphocytes and is divided 
into two subtypes with or without variable gene H rearrangement for coding of immunoglobulin production (the VH mutation) with good and 
poor prognosis, respectively. By means of FISH technique, both VH
+ and VH
– CLL are further segregated into subsets, characterized by 
deletion 17p, deletion 11q, trisomy 12, deletion 6p, deletion 13q and other subtypes including one subtype with a normal FISH investigation. 
These subgroups constitute entities with different prognosis and need of treatment.
After the genetically transmission of the primary stem cell mutation, the differentiation of the mutated B lymphocyte goes through a number 
of stages, ﬁ  rst a marginal-zone(MZC)-like naïve-B-CD5+ stage, from where many or perhaps most cell line die, while del 17p, del 11q,tri 12, 
del 13q etc. survive via ampliﬁ  cation in the abnormal stroma of the lymphoid tissue of CLL with marked cytokine stimulation and marked 
autoimmune micro-regulation. These genetic phenotypes with selective advantage in the CLL stroma [5] do not reﬂ  ect the so far unknown 
genuine inherited DNA-alteration of the ﬁ  rst somatic mutation.18
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become homozygous for a recessive neoplasma 
causing gene [40–43]. During the progression of 
tumor and under the influence of subsequent 
mitoses, carcinogenous hits and somatic mutations 
(Figs. 1 and 2), the initial mutation in only one allel 
of a tumor suppressor gene or a DNA repair gene 
will often cause a loss of the wild-type allel, if the 
cell survive these damages at all. The initial herit-
able gene or genes are often lost or mutated 
somatically in this multistep evolution of tumor 
[41–43].
However, in spite of multiple damages some 
mutated cell lines survive leading to “cancer”. This 
diversity of surviving, mutated clones caused by 
multiple monoallelic genes explains most likely 
the pleiotypic appearance of subsets of diagnoses 
in families with clustering of CLL and related LDs. 
Such asynchronous replicating monoallelic genes 
are often either genomic imprinted genes or genes 
subjected to X-chromosome inactivation [44]. 
While a sole X-chromosome inactivation hardly 
has support from data so far, genomic imprinting 
seems a likely mechanism [45] giving a reasonable 
explanation of the otherwise elusive dominant 
inheritance of the lymphoproliferative disorders 
with unexplained pleiotyphy and birth order 
effect.
Genomic imprinting is a non-Mendelian gene 
expression depending upon the parent that transmit 
it and where the mechanism which silences the 
maternal or the paternal copy is epigenetic, mean-
ing outside the genes [37–39, 46–51]. This 
pregnancy-related growth-factor segregation, 
where the mother selects the load of paternally and 
maternally genes for her offspring is presumably 
a normal physiological mechanism. However, the 
maternal selection of monoallelic genes for her 
offspring is hardly left to sheer coincidence. Evi-
dently, this master plan comprises a mode so that 
the mother can “remember the haplo-load” from 
her past and present male partners. In other words, 
the mother must be able to operate a mechanism 
which can remember the paternal genes and that 
precise mechanism could well be the pregnancy 
related microchimerism [52–54]. Imprinted genes 
are monoallelically expressed and regulated inde-
pendently of spermiogenesis and oogenesis by 
allele-specific epigenetic modifiers (silencer) 
where DNA methylation and/or modiﬁ  cations of 
histones are well described mechanisms [55]. 
Related to the parent — offspring transmission of 
CLL and other subsets of LD, one possible 
mechanism available for the epigenetic DNA 
methylation could be the physiological pregnancy-
related microchimerism between mother and fetus, 
based on the normal trafﬁ  c of lymphocytes and 
monocytes across the feto-maternal (utero-placen-
tal) barrier [52–54]. In each pregnancy, fetal cells 
are transplanted lifelong into the mother so that the 
mother accumulates increased tolerance to non-self 
from the paternal half of the fetus in step with an 
increased number of pregnancies and an increased 
number of male partners [56–59].
The parent´s age and the birth-order effect were 
originally united parameters in Haldane and 
Smith´s test from 1947 [60,61] based on the simple 
assumption that if a genetic malformation in a child 
depends on the age of the father, the disease of the 
child is most likely due to mutation; if it depends 
on the age of the mother the impact is uncertain; 
and if “the number of previous children is the main 
factor, it probably acts through biochemical reac-
tions between mother an child” [62]. In contem-
porary terms, the demonstration of a paternal 
birth-order could be equal to “the number of previ-
ous children as the main factor”. Such a genetic 
mediation of a growth-factor mosaic comprising 
maternal or paternal growth-factor enhancers or 
inhibitors with maternal imprinting, viz. maternal 
silence of paternal LD-genes, and a marked male 
predominance in CLL is perfectly in accordance 
with genomic imprinting., viz. a non-Mendelian 
gene expression depending upon the parent that 
transmit it and where the mechanism which 
silences the maternal or the paternal copy is epi-
genetic.
Genomic imprinting is in favour of adjustment 
of different maternal resources to her offspring to 
maximize maternal ﬁ  tness [63]. Perhaps also to 
prevent paternal genetic predominance in those 
cases where the female has been mating with many 
highly selected males. Avian biology learned us 
extreme examples where the female under cross-
mating by males even maintain the sub-species 
[64]. We can only speculate on the elusive monoal-
lelic polygenes for the growth-factors involved in 
familial CLL and LDs and how they vanish in the 
multistep evolution of tumor under the inﬂ  uence 
of multiple somatic mutations. The identiﬁ  cation 
of these genes and the interpretation of their impact 
on RR of subsets of LD must be based on insight 
into the mode they are transferred from generation 
to generation. In this process we want to point out 
the resemblance to genomic imprinting. Much of 19
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what is known today on the genetics of CLL and 
related LDs seem to match genomic imprinting 
where the likely memory-mechanism of the mother 
to recruit and select parental monoallelic genes for 
her offspring could well be her pregnancy related 
microchimerism so that genomic imprinting and 
pregnancy related microchimerism are linked 
together in an operative system.
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